The CALGB is comprised of 28 academic medical centers and over 200 affiliated community hospitals joined in the pursuit of improved cancer treatment and better understanding of tumor biology via the conduct of controlled clinical trials. Over 4000 members of the Group including oncology physicians, statisticians, clinical research associates, oncology nurses, pharmacists, epidemiologists, and basic scientists participate in these studies. From 25-35 phase III protocols are active at any one time, along with Phase II and Phase I studies that provide preliminary data required for the appropriate design of large scale randomized trials. In 2001 the CALGB accrued nearly 6662 entries to its protocols. Multidisciplinary disease committees of the Group design and implement protocols for the treatment of patients with leukemia, lymphoma, breast, respiratory, GI and GU cancer and melanoma. Modality committees, including Leukemia Correlative Sciences, Solid Tumor Correlative Sciences, Pharmacology and Experimental Therapeutics, Surgery, Pathology, Radiation Oncology, Transplant, Cancer in the Elderly, Cancer Control and Health Outcomes, Oncology Nursing, and Clinical Research Associates serve as the sites for planning and implementing new approaches for these disciplines. Major areas of emphasis in CALGB include development of innovative treatments for patients with cancer;studies of molecular predictors of prognosis and response to therapy;studies of the pharmacokinetics, pharmacodynamics and pharmacogenetics of new and established anticancer drugs;evaluation of minimally invasive surgical techniques;determining the cost and cost-effectiveness of new cancer therapies;evaluating the impact of cancer and its treatment on the quality of life of cancer patients and their caregivers;developing new strategies for cancer prevention;and addressing the needs of special populations, particularly minorities and the elderly. A new activity in Cancer Imaging will be initiated during the coming grant period in an effort to better integrate novel imaging science into cancer treatment studies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
3U10CA037447-25S2
Application #
8140729
Study Section
Special Emphasis Panel (ZCA1-SRRB-E (J1))
Program Officer
Minasian, Lori M
Project Start
1983-09-30
Project End
2010-05-31
Budget Start
2008-06-01
Budget End
2010-05-31
Support Year
25
Fiscal Year
2010
Total Cost
$122,509
Indirect Cost
Name
University of Chicago
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
005421136
City
Chicago
State
IL
Country
United States
Zip Code
60637
Orchard, Tonya S; Andridge, Rebecca R; Yee, Lisa D et al. (2018) Diet Quality, Inflammation, and Quality of Life in Breast Cancer Survivors: A Cross-Sectional Analysis of Pilot Study Data. J Acad Nutr Diet 118:578-588.e1
Parsons, J Kellogg; Pierce, John P; Mohler, James et al. (2018) Men's Eating and Living (MEAL) study (CALGB 70807 [Alliance]): recruitment feasibility and baseline demographics of a randomized trial of diet in men on active surveillance for prostate cancer. BJU Int 121:534-539
Mandelblatt, Jeanne S; Cai, Ling; Luta, George et al. (2017) Frailty and long-term mortality of older breast cancer patients: CALGB 369901 (Alliance). Breast Cancer Res Treat 164:107-117
Himelstein, Andrew L; Foster, Jared C; Khatcheressian, James L et al. (2017) Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial. JAMA 317:48-58
Holstein, Sarah A; Jung, Sin-Ho; Richardson, Paul G et al. (2017) Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. Lancet Haematol 4:e431-e442
Basch, Ethan; Dueck, Amylou C; Rogak, Lauren J et al. (2017) Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials. JAMA Oncol 3:1043-1050
Hacker, Eileen Danaher; Kim, Inah; Park, Chang et al. (2017) Real-time Fatigue and Free-Living Physical Activity in Hematopoietic Stem Cell Transplantation Cancer Survivors and Healthy Controls: A Preliminary Examination of the Temporal, Dynamic Relationship. Cancer Nurs 40:259-268
Hacker, Eileen Danaher; Fink, Anne M; Peters, Tara et al. (2017) Persistent Fatigue in Hematopoietic Stem Cell Transplantation Survivors. Cancer Nurs 40:174-183
Ji, YongLi; Rounds, Tiffany; Crocker, Abigail et al. (2016) The Effect of Atorvastatin on Breast Cancer Biomarkers in High-Risk Women. Cancer Prev Res (Phila) 9:379-84
Zimmerman, Collin; Atherton, Pamela J; Pachman, Deirdre et al. (2016) MC11C4: a pilot randomized, placebo-controlled, double-blind study of venlafaxine to prevent oxaliplatin-induced neuropathy. Support Care Cancer 24:1071-8

Showing the most recent 10 out of 42 publications